GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (TSX:HBP) » Definitions » Cyclically Adjusted PB Ratio

Helix BioPharma (TSX:HBP) Cyclically Adjusted PB Ratio : (As of Jun. 01, 2025)


View and export this data going back to 1996. Start your Free Trial

What is Helix BioPharma Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Helix BioPharma Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Helix BioPharma's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helix BioPharma Cyclically Adjusted PB Ratio Chart

Helix BioPharma Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.84 16.58 6.04 10.19 17.42

Helix BioPharma Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.11 13.78 17.42 14.89 -

Competitive Comparison of Helix BioPharma's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Helix BioPharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Helix BioPharma's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helix BioPharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Helix BioPharma's Cyclically Adjusted PB Ratio falls into.


;
;

Helix BioPharma Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Helix BioPharma's Cyclically Adjusted Book per Share for the quarter that ended in Jan. 2025 is calculated as:

For example, Helix BioPharma's adjusted Book Value per Share data for the three months ended in Jan. 2025 was:

Adj_Book=Book Value per Share/CPI of Jan. 2025 (Change)*Current CPI (Jan. 2025)
=-0/127.4427*127.4427
=0.000

Current CPI (Jan. 2025) = 127.4427.

Helix BioPharma Quarterly Data

Book Value per Share CPI Adj_Book
201504 0.584 99.710 0.746
201507 0.403 100.579 0.511
201510 0.255 100.500 0.323
201601 0.134 100.184 0.170
201604 0.235 101.370 0.295
201607 0.177 101.844 0.221
201610 0.050 102.002 0.062
201701 -0.010 102.318 -0.012
201704 -0.080 103.029 -0.099
201707 -0.001 103.029 -0.001
201710 0.106 103.424 0.131
201801 0.008 104.056 0.010
201804 -0.074 105.320 -0.090
201807 -0.074 106.110 -0.089
201810 -0.079 105.952 -0.095
201901 -0.079 105.557 -0.095
201904 -0.087 107.453 -0.103
201907 -0.147 108.243 -0.173
201910 0.002 107.927 0.002
202001 0.004 108.085 0.005
202004 0.180 107.216 0.214
202007 0.090 108.401 0.106
202010 0.098 108.638 0.115
202101 0.133 109.192 0.155
202104 0.046 110.851 0.053
202107 -0.049 112.431 -0.056
202110 -0.096 113.695 -0.108
202201 -0.143 114.801 -0.159
202204 -0.061 118.357 -0.066
202207 0.009 120.964 0.009
202210 -0.025 121.517 -0.026
202301 0.056 121.596 0.059
202304 0.023 123.571 0.024
202307 -0.019 124.914 -0.019
202310 0.014 125.310 0.014
202401 -0.006 125.072 -0.006
202404 -0.008 126.890 -0.008
202407 -0.002 128.075 -0.002
202410 -0.028 127.838 -0.028
202501 0.000 127.443 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Helix BioPharma  (TSX:HBP) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Helix BioPharma Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Helix BioPharma's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Helix BioPharma Business Description

Traded in Other Exchanges
Address
40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.